# Brexpiprazole

Source: https://onco.cc/drugs/da-brexpiprazole/  
OnCo record `da-brexpiprazole` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Brexpiprazole has a US indication for agitation in Alzheimer’s dementia after other causes are considered. Antipsychotics increase mortality in elderly people with dementia-related psychosis.

## Summary

It is not an as-needed sedative. Boxed warning: antipsychotics increase mortality in elderly people with dementia-related psychosis. Look first for pain, delirium, and unmet need.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-21
- Tags: dementia-atlas
- Brand: Rexulti
- Modality: small molecule
- Mechanism: Antipsychotic used for agitation associated with dementia due to Alzheimer’s disease. It does not treat memory loss.
- Approvals: US 2023: Agitation associated with dementia due to Alzheimer’s disease

## Sources

- FDA agitation approval: https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-agitation-symptoms-associated-dementia-due-alzheimers-disease

## Connected records

- diagnoses: [Alzheimer’s disease](https://onco.cc/diagnoses/alzheimers-disease/)

---
JSON: https://onco.cc/api/v1/entities/da-brexpiprazole.json